文章：

未接受新辅助治疗后手术的食管癌患者的生存结局

Survival Outcomes of Patients with Esophageal Cancer Who Did Not Proceed to Surgery after Neoadjuvant Treatment

原文发布日期：10 August 2023

DOI: 10.3390/cancers15164049

类型: Article

开放获取: 是

英文摘要：

Background: This retrospective study examined outcomes in esophageal squamous cell carcinoma (ESCC) patients who did not undergo surgical resection after neoadjuvant chemoradiotherapy (nCRT). Methods: Patients receiving nCRT between 2012 and 2020 were divided into two groups: group 1 (scheduled surgery) and group 2 (no surgery). Group 2 was further categorized into subgroups based on reasons for not proceeding to surgery: group 2a (disease progression), group 2b (poor general conditions), and group 2c (patient refusal). Overall survival (OS) was the primary outcome. Results: Group 1 comprised 145 patients, while subgroups 2a, 2b, and 2c comprised 24, 16, and 31 patients, respectively. The 3-year OS rate was significantly lower in group 2 compared with group 1 (34% versus 56%,p< 0.001). A subgroup analysis showed varying 3-year OS rates: 13% for group 2a, 25% for group 2b, and 58% for group 2c (p< 0.001). Propensity score matching for group 2c and group 1 revealed no significant difference in 3-year OS rates (p= 0.91). Conclusion: One-third of ESCC patients receiving nCRT did not undergo surgical resection. Overall survival in this group was generally poorer, except for those who refused surgery (group 2c).

摘要翻译： 

背景：本研究回顾性分析了接受新辅助放化疗（nCRT）后未行手术切除的食管鳞状细胞癌（ESCC）患者的预后情况。方法：将2012年至2020年间接受nCRT的患者分为两组：第一组（计划手术）和第二组（未手术）。根据未手术原因将第二组进一步分为三个亚组：2a组（疾病进展）、2b组（全身状况差）和2c组（患者拒绝手术）。主要观察指标为总生存期（OS）。结果：第一组包含145例患者，而亚组2a、2b和2c分别包含24例、16例和31例患者。第二组的3年OS率显著低于第一组（34%对56%，p<0.001）。亚组分析显示各亚组3年OS率存在差异：2a组为13%，2b组为25%，2c组为58%（p<0.001）。对2c组与第一组进行倾向性评分匹配后，两组3年OS率无显著差异（p=0.91）。结论：约三分之一的ESCC患者在接受nCRT后未行手术切除。该组患者总体生存率普遍较差，但拒绝手术者（2c组）例外。

原文链接：

Survival Outcomes of Patients with Esophageal Cancer Who Did Not Proceed to Surgery after Neoadjuvant Treatment